Lei Zhang

US Patent:

6599692, Jul 29, 2003

Filed:

Sep 14, 1999

Appl. No.:

09/395448

Inventors:

Casey C. Case - San Mateo CA
Lei Zhang - San Francisco CA

Assignee:

Sangamo BioScience, Inc. - Richmond CA

International Classification:

C12Q 102

US Classification:

435 4, 435 6, 536 231

Abstract:

The present invention provides methods of regulating gene expression using recombinant zinc finger proteins, for functional genomics and target validation applications.

US Patent:

6711315, Mar 23, 2004

Filed:

Nov 9, 2001

Appl. No.:

10/008469

Inventors:

Victor Joseph - Fremont CA
Khalid Ahmad - Thousand Oaks CA
Jie Zhou - Simi Valley CA
Lei Zhang - Simi Valley CA

Assignee:

Avrio Technologies, Inc. - Simi Valley CA

International Classification:

G02B 635

US Classification:

385 17, 385 18

Abstract:

The optical switch of the present invention advantageously comprises a three dimensional architecture capable of taking input optical signals launched in a first direction, deflecting the signals in a second direction and again in a third direction, preferably orthogonal to the first direction, with no moving parts. The signals are collected at an elevated level without passing through additional nodes. Preferably, incoming beams migrating in an x-direction along a bottom layer are steered in a z-direction to an elevated layer comprising sloped stepped mirror surfaces or a parabolic mirror surface. In an alternate embodiment, a wave guide based optical switch advantageously steers input optical signals from a bottom wave guide layer to an elevated wave guide layer via vertical coupling. The beams are then merged into a collection channel and directly coupled into output fibers without passing through additional transition or cross nodes. In another alternate embodiment, an optical switch include two identical functional plates comprising an array of identically sized and shaped transmissive blocks with stationary inclined electro-optic reflective surfaces.

US Patent:

6777185, Aug 17, 2004

Filed:

Aug 9, 2001

Appl. No.:

09/925796

Inventors:

Casey C. Case - San Mateo CA
Lei Zhang - Davis CA
Fyodor Urnov - Richmond CA

Assignee:

Sangamo Biosciences, Inc. - Richmond CA

International Classification:

C12Q 168

US Classification:

435 6, 4353201, 435 691, 536 231, 536 234

Abstract:

The present invention provides methods of regulating gene expression using recombinant zinc finger proteins, for functional genomics and target validation applications.

US Patent:

7235354, Jun 26, 2007

Filed:

May 12, 2004

Appl. No.:

10/843944

Inventors:

Casey C. Case - San Mateo CA, US
Lei Zhang - Davis CA, US
Fyodor Urnov - Richmond CA, US

Assignee:

Sangamo Biosciences, Inc. - Richmond CA

International Classification:

C12Q 1/00
C12Q 1/68
C12N 15/11

US Classification:

435 4, 435 6, 536 231, 536 241

Abstract:

The present invention provides methods of regulating gene expression using recombinant zinc finger proteins, for functional genomics and target validation applications.

US Patent:

7534775, May 19, 2009

Filed:

Apr 7, 2005

Appl. No.:

11/101095

Inventors:

H. Steve Zhang - Richmond CA, US
Lei Zhang - Davis CA, US

Assignee:

Sangamo Biosciences, Inc. - Richmond CA

International Classification:

A61K 48/00
C07H 21/02
C07H 21/04

US Classification:

514 44, 536 231

Abstract:

Methods and compositions are provided for modulating cardiac contractility by regulating transcription of the phsopholamban gene using engineered zinc finger proteins.

US Patent:

7972854, Jul 5, 2011

Filed:

Feb 3, 2005

Appl. No.:

10/587723

Inventors:

Jeffrey C. Miller - San Francisco CA, US
Lei Zhang - Davis CA, US

Assignee:

Sangamo Biosciences, Inc. - Richmond CA

International Classification:

C12N 15/00

US Classification:

435440, 435455, 435463, 435468, 435471

Abstract:

Disclosed herein are methods and compositions for targeted cleavage of a genomic sequence, targeted alteration of a genomic sequence, and targeted recombination between a genomic region and an exogenous polynucleotide homologous to the genomic region.

US Patent:

8349810, Jan 8, 2013

Filed:

Jun 22, 2011

Appl. No.:

13/165866

Inventors:

Jeffrey C. Miller - San Francisco CA, US
Lei Zhang - Davis CA, US

Assignee:

Sangamo BioSciences, Inc. - Richmond CA

International Classification:

A61K 48/00
C12N 5/0783
C12N 5/074
C12N 5/0789
C12N 15/00

US Classification:

514 44R, 424 9321, 435372, 4353723, 435455

Abstract:

Disclosed herein are methods and compositions for targeted cleavage of a genomic sequence, targeted alteration of a genomic sequence, and targeted recombination between a genomic region and an exogenous polynucleotide homologous to the genomic region. The compositions include fusion proteins comprising a cleavage domain (or cleavage half-domain) and an engineered zinc finger domain, as well as polynucleotides encoding same. Fusion proteins comprising cleavage half-domains are used in pairs to reconstitute a functional cleavage domain. In these fusion proteins, the zinc finger domain can be N-terminal to the cleavage half-domain, or the cleavage half-domain can be N-terminal to the zinc finger domain. The availability of fusion endonucleases having these different polarities allows targeting of zinc finger endonucleases either to opposite strands of the DNA target or to the same strand of the DNA target, thereby increasing the number of possible sequences which can be targeted and cleaved by the fusion proteins.

US Patent:

8551945, Oct 8, 2013

Filed:

Feb 4, 2010

Appl. No.:

12/658258

Inventors:

Carolyn Dent - Richmond CA, US
Josee Laganiere - El Cerrito CA, US
Xiangdong Meng - San Pablo CA, US
David Paschon - Oakland CA, US
Siyuan Tan - Alameda CA, US
Lei Zhang - Davis CA, US
Steve H. Zhang - Richmond CA, US

Assignee:

Sangamo BioSciences, Inc. - Richmond CA

International Classification:

A61K 38/00
A61K 38/28
A61P 3/10
A61P 7/12
A61P 25/02
C12N 5/00
C12N 5/02
C07K 1/00
C07K 14/00
C07K 16/00
C07K 17/00
C07H 21/04

US Classification:

514 69, 514 182, 435325, 530400, 536 235

Abstract:

Disclosed herein are methods and compositions for treating neuropathies by modulating endogenous NT-3 of GDNF gene expression.